GLP-3 RT

GLP-3 RT-2 represents a next-generation approach to incretin receptor agonism. While classical GLP-1 receptor agonists (like semaglutide and liraglutide) target only the GLP-1 receptor, newer research has focused on multi-receptor agonists that simultaneously engage GLP-1, GIP, and glucagon receptors. This compound is designed to leverage the growing understanding that metabolic regulation involves complex interplay between multiple incretin and glucagon pathways. The GLP-1 receptor axis, when activated, stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways. GIP (glucose-dependent insulinotropic polypeptide) receptor activation enhances beta-cell function and, when combined with GLP-1 activity, produces greater metabolic effects than GLP-1 alone — as demonstrated by the success of tirzepatide (a dual GIP/GLP-1 agonist). Research on this class of compounds is in relatively early stages. The rationale for multi-receptor targeting stems from clinical observations that dual and triple agonists produce superior metabolic outcomes compared to single-agonist approaches, as each receptor pathway contributes distinct physiological effects that are complementary rather than redundant.

GLP-3 RT-2 represents a next-generation approach to incretin receptor agonism. While classical GLP-1 receptor agonists (like semaglutide and liraglutide) target only the GLP-1 receptor, newer research has focused on multi-receptor agonists that simultaneously engage GLP-1, GIP, and glucagon receptors. This compound is designed to leverage the growing understanding that metabolic regulation involves complex interplay between multiple incretin and glucagon pathways. The GLP-1 receptor axis, when activated, stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways. GIP (glucose-dependent insulinotropic polypeptide) receptor activation enhances beta-cell function and, when combined with GLP-1 activity, produces greater metabolic effects than GLP-1 alone — as demonstrated by the success of tirzepatide (a dual GIP/GLP-1 agonist). Research on this class of compounds is in relatively early stages. The rationale for multi-receptor targeting stems from clinical observations that dual and triple agonists produce superior metabolic outcomes compared to single-agonist approaches, as each receptor pathway contributes distinct physiological effects that are complementary rather than redundant.

As a novel research compound, standardized dosing protocols are not yet established. Related multi-receptor agonists have been studied at doses ranging from low microgram to milligram scales in preclinical models.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.